Suppliers and packagers for generic pharmaceutical drug: LEUPROLIDE ACETATE

LEUPROLIDE ACETATE

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Invagen Pharms	LEUPROLIDE ACETATE FOR DEPOT SUSPENSION	leuprolide acetate	FOR SUSPENSION;INTRAMUSCULAR	205054	NDA	CIPLA USA INC.	69097-909-50	1 KIT in 1 CARTON (69097-909-50) * 2 mL in 1 VIAL, SINGLE-DOSE (69097-950-32) * 2 mL in 1 SYRINGE (69097-960-31)	2022-07-15
Invagen Pharms	LEUPROLIDE ACETATE FOR DEPOT SUSPENSION	leuprolide acetate	FOR SUSPENSION;INTRAMUSCULAR	205054	NDA	Avyxa Pharma, LLC	83831-134-01	1 KIT in 1 CARTON (83831-134-01) * 2 mL in 1 VIAL, SINGLE-DOSE (83831-150-22) * 2 mL in 1 SYRINGE (83831-135-02)	2025-03-26
Abbvie Endocrine Inc	LUPRON DEPOT	leuprolide acetate	INJECTABLE;INJECTION	020011	NDA	AbbVie Inc.	0074-3641-03	1 KIT in 1 CARTON (0074-3641-03) * 1 mL in 1 SYRINGE * 1 mL in 1 PACKET	1990-10-22
Abbvie Endocrine Inc	LUPRON DEPOT	leuprolide acetate	INJECTABLE;INJECTION	020011	NDA	AbbVie Inc.	0074-3641-71	1 KIT in 1 CARTON (0074-3641-71) * 1 mL in 1 SYRINGE * 1 mL in 1 PACKET	1990-10-22
Abbvie Endocrine Inc	LUPRON DEPOT	leuprolide acetate	INJECTABLE;INJECTION	019732	NDA	AbbVie Inc.	0074-3642-03	1 KIT in 1 CARTON (0074-3642-03) * 1 mL in 1 SYRINGE * 1 SWAB in 1 PACKET	1989-01-26
Abbvie Endocrine Inc	LUPRON DEPOT	leuprolide acetate	INJECTABLE;INJECTION	020708	NDA	AbbVie Inc.	0074-3663-03	1 KIT in 1 CARTON (0074-3663-03) * 1.5 mL in 1 SYRINGE * 1 mL in 1 PACKET	2010-11-08
Abbvie Endocrine Inc	LUPRON DEPOT	leuprolide acetate	INJECTABLE;INJECTION	020517	NDA	AbbVie Inc.	0074-3346-03	1 KIT in 1 CARTON (0074-3346-03) * 1.5 mL in 1 SYRINGE * 1 SWAB in 1 PACKET	1995-12-22

LEUPROLIDE ACETATE DRUG: KEY SUPPLY CHAIN CONSIDERATIONS

Last updated: February 19, 2026

This analysis identifies critical suppliers and potential supply chain vulnerabilities for Leuprolide Acetate, a gonadotropin-releasing hormone (GnRH) agonist used in treating hormone-sensitive cancers and other conditions. The supply chain involves complex peptide synthesis, sterile manufacturing, and global distribution. Disruptions can arise from raw material sourcing, manufacturing capacity, regulatory approvals, and geopolitical factors.

WHO ARE THE PRIMARY LEUPROLIDE ACETATE MANUFACTURERS?

Key manufacturers involved in the production and commercialization of Leuprolide Acetate formulations include:

• AbbVie: Through its acquisition of Allergan, AbbVie markets leuprolide acetate under the brand name Lupron Depot®. This is a significant market player.
• Myovant Sciences (Sumitomo Pharma): Markets relugolix, a GnRH antagonist, which competes with leuprolide acetate in certain indications. While not a direct leuprolide acetate manufacturer, their product represents a competitive therapeutic option impacting market dynamics.
• Teva Pharmaceutical Industries: Has developed and marketed generic versions of leuprolide acetate, increasing market accessibility and competition.
• Fresenius Kabi: Offers leuprolide acetate injections, contributing to the generic market supply.
• Various Chinese API manufacturers: A substantial portion of the Active Pharmaceutical Ingredient (API) for leuprolide acetate is produced by Chinese companies. These include, but are not limited to, APIsourcing.com (a sourcing platform listing multiple suppliers), Wuhan Dahua Pharmaceutical Co., Ltd., and Qilu Pharmaceutical Co., Ltd. (often listed as a potential or actual supplier in trade databases).

These entities operate at different levels of the supply chain, from API synthesis to finished drug product manufacturing and global distribution. The landscape is dynamic, with generic competition intensifying.

WHAT ARE THE CRITICAL RAW MATERIALS AND INTERMEDIATES REQUIRED FOR LEUPROLIDE ACETATE SYNTHESIS?

Leuprolide acetate is a synthetic nonapeptide. Its synthesis requires specialized amino acids and peptide coupling reagents. The primary components and intermediates include:

• Protected Amino Acids:
  • p-Glu-His-Trp-Ser-Tyr-D-Leu-Leu-Arg-Pro-NHEt (the peptide backbone)
  • Specifically, protected forms of L-Glutamic Acid (p-Glu), L-Histidine (His), L-Tryptophan (Trp), L-Serine (Ser), L-Tyrosine (Tyr), L-Leucine (Leu), L-Arginine (Arg), and L-Proline (Pro).
  • The "D-Leu" is a critical unnatural amino acid, the synthesis of which is a specialized process.
• Peptide Coupling Reagents:
  • Reagents like HOBt (Hydroxybenzotriazole), DIC (N,N'-Diisopropylcarbodiimide), HATU (1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate), and HBTU (O-Benzotriazole-N,N,N',N'-tetramethyl-uronium-hexafluorophosphate) are used to facilitate peptide bond formation.
• Protecting Groups:
  • Various protecting groups (e.g., Boc, Fmoc, tBu, Trt) are used to selectively protect reactive functional groups on amino acids during synthesis.
• Solvents and Reagents:
  • High-purity solvents such as DMF (Dimethylformamide), DCM (Dichloromethane), and Acetonitrile are essential.
  • Reagents for deprotection and final salt formation (acetate).
• Excipients for Formulation:
  • For depot formulations, materials like polylactic-co-glycolic acid (PLGA) are critical.
  • Water for injection, mannitol, and other stabilizers.

The supply of these components, particularly the D-Leu and specialized coupling reagents, can be concentrated among a limited number of fine chemical manufacturers.

WHERE ARE THE PRIMARY MANUFACTURING LOCATIONS FOR LEUPROLIDE ACETATE API AND FINISHED PRODUCT?

Manufacturing of leuprolide acetate is geographically diverse, with key hubs in:

• United States: Significant API and finished product manufacturing, especially by established pharmaceutical companies like AbbVie and contract manufacturing organizations (CMOs).
• Europe: Several European countries host API and finished product manufacturing, often by specialized peptide synthesis companies and generic drug manufacturers.
• China: A major global source for leuprolide acetate API. Numerous chemical synthesis companies in China are capable of producing the peptide.
• India: Also a significant contributor to API production and increasingly involved in finished product manufacturing for generic markets.

Table 1: Key Manufacturing Hubs and Their Roles

Region	Primary Role(s)	Key Considerations
United States	API Synthesis, Finished Product Manufacturing	High regulatory standards, established infrastructure, potential for domestic supply security.
Europe	API Synthesis, Finished Product Manufacturing	Strong regulatory oversight, specialized peptide manufacturers, potential for supply chain diversification.
China	API Synthesis	Cost-effectiveness, high volume production capacity, reliance on global shipping, potential for quality variations.
India	API Synthesis, Finished Product Manufacturing	Cost-effectiveness, growing regulatory compliance, significant generics market presence.

The dependence on Chinese API suppliers presents a geopolitical and logistical risk.

WHAT ARE THE KEY PATENTS AND EXCLUSIVITY PERIODS FOR LEUPROLIDE ACETATE PRODUCTS?

The patent landscape for leuprolide acetate is complex, primarily revolving around:

• Composition of Matter Patents: The original patents for leuprolide itself have long expired.
• Formulation Patents: Patents protecting specific formulations, such as the depot injection systems, are critical for branded products. For example, Lupron Depot® has had multiple formulation patents, with some expiring over time, enabling generic entry.
• Method of Use Patents: Patents claiming specific therapeutic applications of leuprolide acetate.
• Manufacturing Process Patents: Patents detailing novel or improved methods of synthesizing the peptide or its formulations.

Example of Patent Exclusivity Impact:

The expiration of key formulation patents for Lupron Depot® has been a catalyst for the introduction of generic leuprolide acetate products. For instance, the initial exclusivity for the 7.5 mg formulation was critical for AbbVie's market position. As these expire, competition increases.

• Lupron Depot-PED® (3-month formulation): Original patents and exclusivity have largely lapsed, paving the way for generics.
• Lupron Depot® (1-month, 4-month, 6-month formulations): These have had varying patent protection timelines. The expiry of these patents, as well as those related to novel delivery mechanisms, has opened the door for biosimilar or generic competition.

Companies developing generic leuprolide acetate must navigate this patent landscape to avoid infringement, often focusing on developing non-infringing processes and formulations.

WHAT ARE THE REGULATORY CONSIDERATIONS AND APPROVAL PATHWAYS FOR LEUPROLIDE ACETATE?

Regulatory approval for leuprolide acetate products is overseen by national and regional health authorities.

• United States (FDA):

  • New Drug Application (NDA): For innovator products.
  • Abbreviated New Drug Application (ANDA): For generic versions. This pathway requires demonstrating bioequivalence to the reference listed drug (RLD).
  • Biologics License Application (BLA): While leuprolide acetate is a synthetic peptide and typically approved via NDA/ANDA, complex manufacturing or novel delivery systems could potentially lead to BLA considerations in the future, though this is uncommon for established peptides.
  • Current Good Manufacturing Practices (cGMP): Strict adherence to FDA cGMP regulations is mandatory for all manufacturing facilities, including API and finished product sites.

• Europe (EMA):

  • Marketing Authorisation Application (MAA): For both innovator and generic products.
  • European Directorate for the Quality of Medicines & HealthCare (EDQM): Certification of Suitability (CEP) is often sought for APIs, demonstrating compliance with European Pharmacopoeia standards.

• Other Regions: Equivalent regulatory bodies in countries like Japan (PMDA), Canada (Health Canada), and Australia (TGA) have their own approval processes.

Key Regulatory Hurdles:

• API Quality: Ensuring consistent purity, potency, and impurity profiles from diverse API suppliers.
• Sterile Manufacturing: Leuprolide acetate formulations are typically sterile injectables, requiring stringent aseptic processing and terminal sterilization validation.
• Lyophilization/Freeze-Drying: Many depot formulations utilize lyophilization, a complex process requiring specialized equipment and expertise.
• Bioequivalence Studies: For generics, robust studies are needed to prove equivalence to the RLD, especially for complex depot formulations.
• Supply Chain Transparency: Regulators are increasingly scrutinizing supply chain integrity and supplier qualification.

WHAT ARE THE POTENTIAL SUPPLY CHAIN RISKS AND MITIGATION STRATEGIES?

The leuprolide acetate supply chain faces several potential risks:

• Raw Material Shortages: Dependence on a limited number of suppliers for specialized amino acids (e.g., D-Leu) or peptide coupling reagents.
  • Mitigation: Diversify raw material suppliers, secure long-term contracts, maintain safety stock, and explore backward integration for critical intermediates.
• API Manufacturing Disruptions: Production issues at key API manufacturers, particularly in China, due to environmental regulations, quality control failures, or geopolitical events.
  • Mitigation: Qualify multiple API suppliers in different geographic regions, conduct thorough audits of supplier facilities, and maintain safety stock of API.
• Finished Product Manufacturing Capacity: Insufficient capacity at CMOs or in-house facilities, especially for sterile lyophilized products, can lead to shortages.
  • Mitigation: Secure dedicated capacity with CMOs, conduct capacity reviews, and build redundancy in manufacturing sites.
• Geopolitical Instability: Trade disputes, tariffs, or political instability in regions heavily involved in API production (e.g., China) can disrupt supply.
  • Mitigation: Map geopolitical risks for key supply nodes, explore regional diversification of manufacturing, and monitor trade policies.
• Regulatory Delays or Withdrawals: Non-compliance with cGMP or quality issues can lead to manufacturing site shutdowns or product recalls.
  • Mitigation: Implement robust quality management systems, conduct regular internal and external audits, and stay abreast of evolving regulatory requirements.
• Logistical Challenges: Shipping disruptions, customs delays, or cold chain failures for temperature-sensitive products.
  • Mitigation: Partner with reliable logistics providers experienced in pharmaceutical cold chain, implement real-time monitoring, and develop contingency plans for transportation.
• Single Source Dependency: Reliance on a single supplier for a critical component or service.
  • Mitigation: Identify alternative suppliers for all critical inputs, even if not currently used.

Table 2: Supply Chain Risk Assessment and Mitigation

Risk Category	Specific Risk Example	Likelihood	Impact	Mitigation Strategies
Raw Material Sourcing	Shortage of protected D-Leucine	Medium	High	Qualify 2-3 alternative D-Leu suppliers. Maintain 6-month safety stock of key raw materials. Engage in strategic partnerships with primary suppliers.
API Manufacturing	Environmental shutdown of a major Chinese API plant	Medium	High	Diversify API sourcing to include manufacturers in India and Europe. Conduct rigorous quality audits for all API suppliers. Establish inventory buffer of 3-6 months of API.
Finished Product Mfg.	Capacity constraints at sterile lyophilization CMOs	Medium	High	Secure long-term manufacturing agreements with multiple qualified CMOs. Conduct regular capacity utilization reviews with partners. Investigate in-house manufacturing options for critical products.
Geopolitical Factors	Increased tariffs on chemical intermediates from China	Low	Medium	Map all supply chain nodes and their geopolitical exposure. Develop contingency plans for alternative sourcing routes. Monitor trade negotiations and policy changes.
Regulatory Compliance	FDA inspection finding leading to production halt	Low	High	Implement a comprehensive Quality Management System (QMS) exceeding cGMP requirements. Conduct pre-inspection readiness assessments. Foster a culture of continuous improvement and regulatory adherence.
Logistics & Distribution	Cold chain breach during international transit	Medium	Medium	Utilize validated cold chain logistics providers with proven track records. Implement advanced temperature monitoring technology (e.g., IoT sensors). Develop robust deviation management procedures for temperature excursions.

WHAT IS THE MARKET DYNAMICS AND COMPETITIVE LANDSCAPE FOR LEUPROLIDE ACETATE?

The market for leuprolide acetate is characterized by:

• Branded Dominance and Generic Erosion: Initially dominated by AbbVie's Lupron Depot®, the market has seen significant erosion due to the entry of numerous generic competitors.
• Complex Formulations: The market includes various depot formulations (1-month, 3-month, 4-month, 6-month), each with its own patent and market dynamics. The complexity of these formulations (e.g., microsphere technology) can create barriers to entry for some generic manufacturers.
• Therapeutic Area Competition: Leuprolide acetate competes with other GnRH agonists, GnRH antagonists (like relugolix), and other hormone therapies across its indications (prostate cancer, endometriosis, uterine fibroids, precocious puberty).
• Price Pressure: The influx of generics has led to substantial price reductions, increasing affordability but also squeezing profit margins.
• Supply Chain Reliability as a Differentiator: For branded and key generic players, demonstrating consistent and reliable supply can be a significant competitive advantage, especially when competitors experience shortages.

Key Competitors and Their Product Offerings:

• AbbVie: Lupron Depot® (innovator, multiple formulations).
• Teva Pharmaceuticals: Generic leuprolide acetate for injection (various strengths and durations).
• Fresenius Kabi: Generic leuprolide acetate for injection.
• Viatris: Generic leuprolide acetate products.
• Various smaller generic manufacturers: Continuously entering the market as patents expire.
• Companies developing biosimil or follow-on versions: While technically a peptide, the regulatory pathway for generics (ANDA) is standard, not biosimilar (BLA), but development efforts are ongoing to replicate complex formulations.

The competitive landscape necessitates robust supply chain management to ensure uninterrupted product availability and maintain market share against aggressive pricing from generic entrants.

KEY TAKEAWAYS

• Leuprolide Acetate supply chains are globally distributed, with a significant reliance on API manufacturing in China and finished product manufacturing in the US, Europe, India, and China.
• Critical raw materials include specialized protected amino acids and peptide coupling reagents, which can be sourced from a limited number of fine chemical suppliers.
• The patent expiry of innovator formulations has led to intense generic competition, driving price erosion and emphasizing the importance of efficient manufacturing and supply chain reliability.
• Regulatory compliance, particularly cGMP for sterile injectables and lyophilized products, is paramount and presents ongoing challenges.
• Supply chain risks include raw material shortages, API manufacturing disruptions, geopolitical instability, logistical failures, and single-source dependencies. Mitigation requires diversification of suppliers, robust quality systems, safety stock, and geopolitical risk assessment.

FAQS

1. What is the primary therapeutic use of Leuprolide Acetate? Leuprolide Acetate is primarily used to treat hormone-sensitive cancers such as prostate cancer and breast cancer. It is also used for endometriosis, uterine fibroids, and central precocious puberty.

2. How does the manufacturing process for Leuprolide Acetate differ from typical small molecule drugs? Leuprolide Acetate is a synthetic peptide, requiring complex solid-phase or solution-phase peptide synthesis, which involves sequential coupling of protected amino acids. This is significantly more complex than the synthesis of typical small molecule drugs.

3. What are the main challenges in ensuring the quality of generic Leuprolide Acetate products? Ensuring bioequivalence for complex depot formulations, maintaining consistent impurity profiles across different API batches and manufacturers, and validating the stability of the peptide in its final dosage form are significant challenges.

4. Which geographic regions pose the greatest geopolitical risk to the Leuprolide Acetate supply chain? Regions heavily involved in API manufacturing, particularly China, present the most significant geopolitical risk due to potential trade disputes, regulatory changes, or political instability.

5. Are there any readily available natural sources for Leuprolide Acetate or its precursors? No, Leuprolide Acetate is a synthetic peptide and does not have natural sources. Its precursors, the amino acids, are naturally occurring, but their modification and synthesis into the final peptide structure are entirely artificial.

CITATIONS

[1] U.S. Food and Drug Administration. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Retrieved from https://www.fda.gov/drugs/therapeutic-equivalence-drug-products/orange-book-approved-drug-products-therapeutic-equivalence-evaluations

[2] European Medicines Agency. (n.d.). About the European Medicines Agency. Retrieved from https://www.ema.europa.eu/en/about-ema

[3] World Health Organization. (n.d.). International Nonproprietary Names (INN) for Pharmaceutical Substances. Retrieved from https://www.who.int/teams/regulation-and-prequalification/policies-and-standards/international-nonproprietary-names

[4] Public Patent databases (e.g., Google Patents, USPTO Patent Search, Espacenet). (Various Dates). Search results for patents related to "Leuprolide Acetate" and its formulations.

[5] Pharmaceutical industry trade publications and market analysis reports (e.g., EvaluatePharma, GlobalData, Fierce Pharma). (Various Dates). Reports on drug market analysis, manufacturing, and supply chains.